Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Briacell Therapeutics Corp (BCTX)

Briacell Therapeutics Corp (BCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 28,548
  • Shares Outstanding, K 36,183
  • Annual Sales, $ 0 K
  • Annual Income, $ -4,790 K
  • EBIT $ -33 M
  • EBITDA $ -33 M
  • 60-Month Beta 1.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.17
  • Most Recent Earnings $-0.07 on 10/28/24
  • Next Earnings Date 12/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 273.77% ( -17.16%)
  • Historical Volatility 107.45%
  • IV Percentile 62%
  • IV Rank 20.45%
  • IV High 1,195.86% on 08/15/24
  • IV Low 36.72% on 12/14/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 78
  • Volume Avg (30-Day) 182
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 9,052
  • Open Int (30-Day) 8,645

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 10/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 1
  • High Estimate -0.30
  • Low Estimate -0.30
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5550 +31.48%
on 11/19/24
0.9499 -23.18%
on 10/23/24
-0.1425 (-16.34%)
since 10/22/24
3-Month
0.4641 +57.23%
on 09/16/24
1.9600 -62.77%
on 09/11/24
-0.0903 (-11.01%)
since 08/22/24
52-Week
0.4641 +57.23%
on 09/16/24
5.9700 -87.78%
on 01/02/24
-3.8403 (-84.03%)
since 11/22/23

Most Recent Stories

More News
BriaCell Announces First Patient Dosed with Bria-OTS™ in Metastatic Breast Cancer Study

BCT.TO : 1.01 (-7.34%)
BCTXW : 0.3350 (+8.03%)
BCTX : 0.7297 (-7.52%)
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BCT.TO : 1.01 (-7.34%)
BCTXW : 0.3350 (+8.03%)
BCTX : 0.7297 (-7.52%)
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13

BCT.TO : 1.01 (-7.34%)
BCTXW : 0.3350 (+8.03%)
BCTX : 0.7297 (-7.52%)
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data

BCT.TO : 1.01 (-7.34%)
BCTXW : 0.3350 (+8.03%)
BCTX : 0.7297 (-7.52%)
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Each October, breast cancer awareness gains momentum through impactful campaigns and advancements in...

ONCY : 0.9541 (-2.64%)
PCSA : 0.8601 (-2.26%)
JAGX : 1.0400 (+5.62%)
BCTX : 0.7297 (-7.52%)
ONC.TO : 1.33 (-2.92%)
RHHBY : 35.4400 (+0.43%)
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study

BCT.TO : 1.01 (-7.34%)
BCTXW : 0.3350 (+8.03%)
BCTX : 0.7297 (-7.52%)
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – September 13, 2023 – USA News Group  –  Sufferers of many different ailments saw reason to grow their hope in 2022 when...

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
FULC : 3.25 (+9.43%)
RNA : 43.25 (+1.62%)
BCTX : 0.7297 (-7.52%)
BCT.TO : 1.01 (-7.34%)
GILD : 90.19 (+0.48%)
Stocks in play: BriaCell Therapeutics Corp.

Announced that it has received approval from FDA on its pivotal registrational study design for Bria-IMT™ ...

BCTX : 0.7297 (-7.52%)
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is needed in the fight against metastatic breast cancer. According to the American Cancer Society, more than 3.1 million women in the United States have a history of...

LLY : 748.01 (-0.25%)
PBYI : 3.00 (+3.45%)
GILD : 90.19 (+0.48%)
IMGN : 31.23 (unch)
BCTX : 0.7297 (-7.52%)
BCT.TO : 1.01 (-7.34%)
There are Positive Developments in the Treatment of Metastatic Breast Cancer

A significant medical breakthrough is desperately needed in the fight against metastatic breast cancer. As it stands right now, metastatic breast cancer has no cure and has proven resistant to many cancer...

LLY : 748.01 (-0.25%)
PBYI : 3.00 (+3.45%)
GILD : 90.19 (+0.48%)
IMGN : 31.23 (unch)
BCTX : 0.7297 (-7.52%)
BCT.TO : 1.01 (-7.34%)

Business Summary

BriaCell Therapeutics Corp. is an immuno-oncology focused biotechnology company. It developed a patented whole-cell vaccine, cancer immunotherapy technology called the `BriaVax` vaccine for cancer. The company's technology consists of Bria-IMT(TM), Bria-OTS(TM) and BriaDx(TM) which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 0.9115
2nd Resistance Point 0.8632
1st Resistance Point 0.7965
Last Price 0.7297
1st Support Level 0.6815
2nd Support Level 0.6332
3rd Support Level 0.5665

See More

52-Week High 5.9700
Fibonacci 61.8% 3.8667
Fibonacci 50% 3.2170
Fibonacci 38.2% 2.5674
Last Price 0.7297
52-Week Low 0.4641

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar